Overview
Board-Certified Infectious Diseases Clinical Pharmacist with over 14 years of experience in both community and academic healthcare settings. Highly results-driven, with a proven track record in building and leading high-performing, innovative teams that deliver measurable improvements in patient care outcomes. Subject matter expert in infectious diseases pharmacotherapy, with an interest in cutting-edge microbiology technologies and the application of artificial intelligence (AI) into healthcare, to enhance decision-making and streamline antimicrobial stewardship practices.
My career began in HIV research at GlaxoSmithKline, where I honed my analytical skills in the pharmaceutical industry. I then pursued a Doctor of Pharmacy degree at UNC Eshelman School of Pharmacy, followed by completing a pharmacy practice residency and a specialty residency in infectious diseases pharmacotherapy at Wake Forest Baptist Health. Since completing my residency, I have dedicated my career to advancing the field of Infectious Diseases and Antimicrobial Stewardship, with a particular focus on incorporating innovative strategies to improve patient care. I currently serve as the Manager of Infectious Diseases Pharmacy Services, where I lead multidisciplinary antimicrobial stewardship and ambulatory Infectious Diseases programs, guide formulary decisions, and optimize patient outcomes, and ensure regulatory compliance. I've built successful teams, implemented cutting-edge stewardship strategies, and driven meaningful reductions in antimicrobial utilization.
I am an active committee member and speaker for prominent national and local professional societies, including the Society of Infectious Diseases Pharmacists (SIDP), the Infectious Diseases Society of America (IDSA), and the Society for Healthcare Epidemiology of America (SHEA). My contributions to these organizations reflect my commitment to staying at the forefront of the field and driving continuous improvement in healthcare practices.
My career began in HIV research at GlaxoSmithKline, where I honed my analytical skills in the pharmaceutical industry. I then pursued a Doctor of Pharmacy degree at UNC Eshelman School of Pharmacy, followed by completing a pharmacy practice residency and a specialty residency in infectious diseases pharmacotherapy at Wake Forest Baptist Health. Since completing my residency, I have dedicated my career to advancing the field of Infectious Diseases and Antimicrobial Stewardship, with a particular focus on incorporating innovative strategies to improve patient care. I currently serve as the Manager of Infectious Diseases Pharmacy Services, where I lead multidisciplinary antimicrobial stewardship and ambulatory Infectious Diseases programs, guide formulary decisions, and optimize patient outcomes, and ensure regulatory compliance. I've built successful teams, implemented cutting-edge stewardship strategies, and driven meaningful reductions in antimicrobial utilization.
I am an active committee member and speaker for prominent national and local professional societies, including the Society of Infectious Diseases Pharmacists (SIDP), the Infectious Diseases Society of America (IDSA), and the Society for Healthcare Epidemiology of America (SHEA). My contributions to these organizations reflect my commitment to staying at the forefront of the field and driving continuous improvement in healthcare practices.
Current Appointments & Affiliations
Medical Associate Professor in the Department of Medicine
·
2025 - Present
Medicine, Infectious Diseases,
Medicine
Recent Publications
A comparison of blood culture diagnostic stewardship across three emergency departments in a healthcare network.
Journal Article Am J Emerg Med · July 2025 BACKGROUND: Blood culture (BCx) diagnostic stewardship is essential for reducing unnecessary treatments, minimizing false-positive results, and improving patient outcomes and hospital resource utilization. The objective of this study was to compare the eff ... Full text Link to item CiteSalvage treatment of Pneumocystis jirovecii pneumonia with micafungin and clindamycin: a case report
Journal Article Ame Medical Journal · March 30, 2025 Background: Pneumocystis jirovecii pneumonia (PJP) causes significant morbidity and mortality in immunocompromised patients. Current therapeutic options for PJP may be limited by toxicities, and alternate therapeutic options with fewer side effects are lim ... Full text CiteImpact of an Algorithm to Triage Patients Discharged From the Emergency Department With Blood Cultures Positive for Staphylococcus aureus or Coagulase-Negative Staphylococcus.
Journal Article J Am Coll Emerg Physicians Open · February 2025 OBJECTIVES: Blood cultures obtained in the emergency department (ED) may become positive after discharge. Healthcare professionals must determine if these results represent true infection or a likely contaminant. An institutional algorithm was developed to ... Full text Link to item CiteEducation, Training & Certifications
University of North Carolina, Chapel Hill ·
2010
Pharm.D.